Physician profile
John S Khoury
NPI 1255549713
$685,723.82
in general payments reported to CMS, 2019-2025
67 companies · $97K in 2025
The $97K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95K · 2020: $60K · 2021: $121K · 2022: $92K · 2023: $120K · 2024: $100K · 2025: $97K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $188K · Travel and Lodging: $52K · Consulting Fee: $31K · Honoraria: $29K · Food and Beverage: $15K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,500 · Education: $491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $188,435.00 |
| Travel and Lodging | $51,811.92 |
| Consulting Fee | $30,535.00 |
| Honoraria | $29,100.00 |
| Food and Beverage | $15,413.46 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,500.00 |
| Education | $491.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $553,825.59 | 2019-2025 | |
| Axsome Therapeutics, INC. | $56,974.31 | 2023-2025 | Sunosi |
| Eisai INC. | $31,496.27 | 2019-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $14,104.94 | 2023-2025 | Lumryz |
| Lilly USA, LLC | $9,484.49 | 2019-2025 | Zepbound, Mounjaro |
| Alexion Pharmaceuticals, INC. | $4,695.72 | 2020-2025 | Soliris, Ultomiris |
| Merck Sharp & Dohme LLC | $2,582.25 | 2019-2023 | Belsomra |
| Eisai Co., Ltd. | $2,420.00 | 2022 | |
| Idorsia Pharmaceuticals US INC | $1,754.98 | 2023 | Quviviq |
| Harmony Biosciences LLC | $1,717.66 | 2020-2025 | Wakix |
| Abbvie INC. | $738.57 | 2022-2025 | |
| Argenx US, INC. | $663.96 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $643.24 | 2019-2025 | Uplizna, Aimovig |
| Inspire Medical Systems, INC. | $440.56 | 2023-2025 | Inspire |
| Teva Pharmaceuticals USA, INC. | $410.22 | 2019-2025 | Austedo Xr, Ajovy |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Khoury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.